Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection
Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection
This partnership will broaden the range of cancer types that can receive Genomic Instability Score results and their homologous recombination deficiency status.Myriad Genetics updates its agreement with Illumina, integrating GIS for broader cancer diagnostics using TruSight Oncology 500 v2.
萬基遺傳更新與illumina的協議，整合GIS以擴大使用TruSight Oncology 500 v2進行癌症診斷。
Quiver AI Summary
Quiver AI 概要
Myriad Genetics has announced an update to its agreement with Illumina, which will allow the inclusion of its Genomic Instability Score (GIS) for Homologous Recombination Deficiency (HRD) in all samples analyzed via Illumina's TruSight Oncology 500 v2 assay. This change broadens the availability of GIS results across various cancer types, enhancing Myriad's oncology product portfolio. The collaboration aims to combine Myriad's HRD technology with Illumina's expertise to create advanced genomic profiling tools and expand clinical research opportunities, particularly for HRD-based therapies. Myriad's MyChoice CDx test, which detects tumors with homologous recombination deficiencies, will be further supported by this strategic partnership, which has evolved since its initial announcement in January 2021.
萬基遺傳宣佈更新與illumina的協議，這將允許在所有通過illumina的TruSight Oncology 500 v2檢測分析的樣本中納入其基因組不穩定性評分（GIS）用於同源重組缺陷（HRD）。這一變化擴大了在不同癌症類型中GIS結果的可獲取性，增強了萬基的腫瘤學產品組合。該合作旨在將萬基的HRD技術與illumina的專長相結合，以創建先進的基因組分析工具並擴展臨床研究機會，特別是針對HRD相關療法。萬基的MyChoice CDx測試，能夠檢測具有同源重組缺陷的腫瘤，將得到這一戰略合作的進一步支持，該合作自2021年1月首次宣佈以來不斷演變。
Potential Positives
潛在的積極因素
- Expansion of collaboration with Illumina allows for the inclusion of Myriad's Genomic Instability Score in all samples analyzed with the TruSight Oncology 500 v2 assay, enhancing diagnostic capabilities.
- Broader availability of GIS results for various cancer types could strengthen Myriad's position in the oncology market and attract more healthcare providers to use their technology.
- The integration of Myriad's HRD technology with Illumina's expertise may boost clinical research opportunities and drive development of companion diagnostics, potentially increasing revenue streams.
- 與illumina的合作擴大了允許運用TruSight Oncology 500 v2檢測分析的所有樣本納入萬基的基因組不穩定性評分，從而增強了診斷能力。
- 更廣泛的GIS結果可用於各種癌症類型，可能會增強萬基在腫瘤學市場的地位，並吸引更多的醫療保健提供者使用他們的技術。
- 萬基的HRD技術與illumina的專業知識的整合，可能會促進臨床研究機會，並推動伴隨診斷的發展，從而潛在地增加營業收入。
Potential Negatives
潛在負面影響
- The press release contains several forward-looking statements that are subject to known and unknown risks and uncertainties which could result in actual outcomes differing materially from expectations.
- Myriad's reliance on the collaboration with Illumina for expanding its technology and product offerings could expose the company to risks related to partnership dependencies and potential changes in the collaboration's terms or effectiveness.
- The announcement primarily highlights the technical aspects of the collaboration but does not provide clear insights into the commercial implications or expected financial benefits, leaving a gap in transparency regarding the partnership's potential impact on revenue and market position.
- 新聞稿包含若干前瞻性聲明，這些聲明受已知和未知風險及不確定性的影響，可能導致實際結果與預期大相徑庭。
- 萬基遺傳對與illumina合作以擴展其科技和產品供應的依賴可能使公司面臨與合作伙伴依賴及潛在合作條款或有效性變更相關的風險。
- 該公告主要強調了合作的技術方面，但沒有明確說明商業意義或預期的財務利益，導致關於夥伴關係對營業收入和市場地位潛在影響的透明度存在缺口。
FAQ
常見問題
What is the latest update from Myriad Genetics regarding Illumina?
萬基遺傳關於illumina的最新更新是什麼？
Myriad Genetics has updated its agreement with Illumina to include its Genomic Instability Score in all samples analyzed with Illumina's TruSight Oncology 500 v2.
萬基遺傳已更新與illumina的協議，在所有與illumina的TruSight Oncology 500 v2分析的樣本中包含其基因組不穩定性評分。
How will the partnership with Illumina affect cancer testing?
與illumina的合作將如何影響癌症檢測？
This partnership will broaden the range of cancer types that can receive Genomic Instability Score results and their homologous recombination deficiency status.
這一夥伴關係將擴大可以獲得基因組不穩定性評分結果及其同源重組缺陷狀態的癌症類型區間。
What technologies are combined in Myriad's tests?
Myriad的檢測中結合了哪些技術？
Myriad's MyChoice CDx test combines tumor sequencing of BRCA1 and BRCA2 with proprietary technologies assessing loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions.
Myriad的MyChoice CDx檢測結合了BRCA1和BRCA2的腫瘤測序與專有技術，評估雜合性缺失、端粒等位基因不平衡以及大規模狀態轉變。
What is the significance of the Genomic Instability Score (GIS)?
基因組不穩定性評分（GIS）的意義是什麼？
The GIS helps identify tumors deficient in homologous recombination, indicating higher susceptibility to certain cancer treatments like platinum drugs and PARP inhibitors.
GIS有助於識別同源重組缺陷的腫瘤，這表示對某些癌症治療如鉑金藥物和PARP抑制劑有更高的敏感性。
How does this collaboration enhance Myriad's oncology product portfolio?
這種合作如何增強Myriad的腫瘤學產品組合？
The inclusion of GIS in Myriad's Precise Tumor clinical reports will strengthen its oncology product offerings, enhancing comprehensive genomic profiling capabilities.
在Myriad的Precise Tumor臨床報告中納入GIS將加強其腫瘤學產品的提供，增強全面的基因組分析能力。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明：這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。
$MYGN Insider Trading Activity
$MYGN內線交易活動
$MYGN insiders have traded $MYGN stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
$MYGN 內部人士在過去 6 個月內在公開市場上交易了 $MYGN 股票 9 次。在這些交易中，0 次爲購買，9 次爲銷售。
Here's a breakdown of recent trading of $MYGN stock by insiders over the last 6 months:
以下是過去 6 個月內內部人士對 $MYGN 股票的近期交易情況：
- PAUL J DIAZ (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 30,000 shares.
- DALE MUZZEY (Chief Scientific Officer) sold 2,100 shares.
- HEINRICH DREISMANN sold 10,000 shares.
- COLLEEN F REITAN sold 46,012 shares.
- MARGARET ANCONA (SVP, Chief of Staff) sold 11,538 shares.
- RASHMI KUMAR sold 7,500 shares.
- DANIEL K SPIEGELMAN has traded it 2 times. They made 0 purchases and 2 sales, selling 7,576 shares.
- 保羅·J·迪亞斯（總裁兼首席執行官）交易了 2 次。他們沒有進行購買，進行了 2 次銷售，出售了 30,000 股。
- 戴爾·穆澤（首席科學官）出售了 2,100 股。
- 海因裏希·德雷斯曼出售了 10,000 股。
- 科琳·F·瑞坦出售了 46,012 股。
- 瑪格麗特·安科納（高級副總裁，首席幕僚）出售了 11,538 股。
- 拉什米·庫瑪出售了 7,500 股。
- 丹尼爾·K·斯皮格爾曼交易了2次。他們沒有購買，進行了2次銷售，出售了7,576股。
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
要跟蹤內部交易，請查看Quiver Quantitative的內部交易特斯拉-儀表。
$MYGN Hedge Fund Activity
$MYGN對沖基金活動
We have seen 130 institutional investors add shares of $MYGN stock to their portfolio, and 106 decrease their positions in their most recent quarter.
我們看到130家機構投資者在最近一個季度增加了$MYGN股票的持股，106家減少了他們的持股。
Here are some of the largest recent moves:
以下是一些最近最大的交易動態：
- GLENVIEW CAPITAL MANAGEMENT, LLC removed 2,486,902 shares (-66.3%) from their portfolio in Q3 2024
- CITADEL ADVISORS LLC removed 1,695,989 shares (-96.1%) from their portfolio in Q3 2024
- CAMBER CAPITAL MANAGEMENT LP removed 1,550,000 shares (-28.2%) from their portfolio in Q3 2024
- WELLINGTON MANAGEMENT GROUP LLP removed 1,545,842 shares (-18.7%) from their portfolio in Q3 2024
- LOOMIS SAYLES & CO L P added 1,326,497 shares (+153.7%) to their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC added 777,499 shares (+17.7%) to their portfolio in Q3 2024
- MORGAN STANLEY removed 491,650 shares (-35.8%) from their portfolio in Q3 2024
- 格倫維爾資本管理公司在2024年第三季度減少了2,486,902股（-66.3%）。
- 城堡顧問公司在2024年第三季度減少了1,695,989股（-96.1%）。
- 坎伯資本管理LP在2024年第三季度減少了1,550,000股（-28.2%）。
- 威靈頓管理集團LLP在2024年第三季度從其投資組合中移除了1,545,842股（-18.7%）
- 洛米斯·賽爾斯公司在2024年第三季度向其投資組合中新增了1,326,497股（+153.7%）
- 千禧管理公司在2024年第三季度向其投資組合中新增了777,499股（+17.7%）
- 摩根士丹利在2024年第三季度從其投資組合中移除了491,650股（-35.8%）
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追蹤對沖基金的股票組合，請查看Quiver Quantitative的機構持股儀表板。
Full Release
全面發佈
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) --
Myriad Genetics, Inc
. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies.
鹽湖城，2024年11月20日（全球新聞社）--
萬基遺傳公司
. (納斯達克: MYGN)，作爲基因檢測和精準醫療的領導者，宣佈與illumina公司（納斯達克: ILMN）更新協議，後者是DNA測序和基於陣列技術的全球領導者。
Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight Oncology 500 v2 (TSO 500 v2). Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status.
萬基的黃金標準基因組不穩定性評分（GIS）將用於確定同源重組缺陷（HRD），並將報告所有通過illumina更新的研究分析檢測 TruSight Oncology 500 v2（TSO 500 v2）的樣本。以前，用於確定HRD的GIS僅作爲一種單獨產品提供。因此，廣泛的癌症類型將接收GIS結果及其HRD狀態。
"We are pleased to expand our collaboration with Illumina and combine the two companies' technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
「我們很高興擴大與Illumina的合作，並結合兩家公司的技術，創建我們認爲是最先進和完整的基因面板，以實現全面基因組分析。」萬基遺傳公司戰略與創新執行副總裁Patrick Burke博士表示。
Combining Myriad's HRD technology, which is used in MyChoice
CDx tumor-based test, with Illumina's expertise in comprehensive genomic profiling will enable Myriad to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types. Broad availability of data and the Myriad GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer.
結合萬基遺傳的HRD科技，此技術用於MyChoice
CDx腫瘤檢測與illumina在全面基因組分析方面的專業知識，將使萬基遺傳能夠拓寬臨床研究機會，並有可能推動HRD基礎療法的CDx開發，涵蓋多種潛在腫瘤類型。廣泛的數據可用性和萬基遺傳GIS平台可能有助於推動疾病位點指示擴展和潛在伴隨診斷產品開發，超越卵巢癌。
"Inclusion of GIS in all Myriad's
Precise Tumor
clinical reports will strengthen the company's oncology product portfolio," said Burke. "Precise Tumor is a pan-cancer solid tumor comprehensive genomic profiling test, leveraging Illumina's current TSO 500 technology."
“將GIS納入萬基遺傳的所有
精準腫瘤
臨床報告將加強公司的腫瘤產品組合，”布爾克表示。「精準腫瘤是一項泛癌症實體瘤的全面基因組分析測試，利用illlumina當前的電訊首科500技術。」
Myriad announced the strategic partnership with Illumina in
January 2021
and has expanded its relationship both
geographically
and
technologically
since that time.
萬基遺傳宣佈與illumina進行戰略合作
2021年1月
並且已在以下方面擴大了其關係
地理範圍
和
科技方面
自那時以來。
About Myriad's MyChoice CDx HRD Companion Diagnostic Test
Myriad's MyChoice CDx is the most comprehensive homologous recombination deficiency (HRD) test, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The
MyChoice test
comprises tumor sequencing of the
BRCA1
and
BRCA2
genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).
關於萬基遺傳MyChoice CDx HRD伴侶診斷測試
萬基遺傳的MyChoice CDx是最全面的同源重組缺陷(HRD)檢測，能夠幫助醫生識別那些失去修復雙鏈DNA斷裂能力的腫瘤患者，這使得他們對如鉑金類藥物或PARP抑制劑等DNA損傷藥物更爲敏感。
MyChoice檢測
包括腫瘤測序的
BRCA1
和
BRCA2
基因和三項專有技術的組合（雜合性缺失、端粒等位基因失衡和大規模狀態轉變）。
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit
.
關於Myriad Genetics
萬基遺傳是一家領先的基因檢測和精準醫學公司，專注於促進所有人的健康和福祉。萬基開發並提供基因檢測，幫助評估疾病發生或疾病進展的風險，並指導各醫療專業領域的治療決策，在這些領域，基因洞察可以顯著改善患者護理並降低醫療成本。欲了解更多信息，請訪問
.
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company's Genomic Instability Score (GIS) will be reported for all samples analyzed with TSO 500 v2, a broader array of cancer types will receive GIS results and their HRD status, the company's agreement with Illumina will expand world-wide access to the company's technology and better position the company's GIS as a potential companion diagnostic across multiple potential tumor types, combining the company's HRD technology with Illumina's expertise in comprehensive genomic profiling will enable the company to broaden clinical research opportunities and potentially drive CDx development for HRD-based therapies across multiple potential tumor types, broad availability of data and the company's GIS platform may help drive disease-site indication expansion and potential companion diagnostic product development beyond ovarian cancer, and the inclusion of GIS in all Myriad's Precise Tumor clinical reports will strengthen the company's oncology product portfolio. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Safe Harbor聲明
本新聞稿包含1995年《私人證券訴訟改革法案》所定義的「前瞻性陳述」，包括公司的基因組不穩定性評分（GIS）將在分析的所有樣本中報告，與電訊首科500 v2分析的更廣泛癌症類型將獲得GIS結果及其HRD狀態，公司的Illumina簽約將擴大全球市場對公司技術的使用，並更好地將公司的GIS定位爲多種潛在腫瘤類型的潛在伴隨診斷，結合公司的HRD技術與Illumina在全面基因組分析方面的專業知識將使公司能夠擴大臨床研究機會，並可能推動基於HRD的療法在多個潛在腫瘤類型中的CDx開發，數據廣泛可用性和公司的GIS平台可能有助於推動疾病部位指示擴展和潛在的伴隨診斷產品開發超出卵巢癌，以及GIS在所有萬基精準腫瘤臨床報告中的納入將增強公司的腫瘤學產品組合。這些「前瞻性陳述」是管理層對於未來事件的預期，截止目前的日期，受已知和未知的風險和不確定性影響，導致實際結果、條件和事件可能與預期存在重大和不利差異。此類因素包括在公司向美國證券交易委員會的備案文件中描述的那些風險，包括公司於2024年2月28日提交的10-K表格年度報告，以及隨時更新的這些風險因素在公司季度報告10-Q表格或當前報告8-K表格中。萬基沒有任何更新或更改任何前瞻性陳述的義務，也明確放棄任何更新或更改的義務，無論是因新信息、未來事件還是其他原因，法律要求除外。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投資者聯繫人
馬特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒體聯繫
Glenn Farrell
(385) 318-3718
PR@myriad.com
